Pleomorphic liposarcoma (PLPS) is a rare subtype of liposarcoma, characterized by the presence of pleomorphic lipoblasts without definitive molecular aberrations; it accounts for less than 5% of all liposarcomas. PLPS is an aggressive cancer that exhibits frequent local recurrence and metastasis, with an overall 5-year survival rate of ~ 60%. Owing to the lack of effective treatment options in inoperable conditions and resistance to chemotherapeutics, novel therapies are required to treat PLPS. Although patient-derived cell lines are a critical tool for basic and pre-clinical research, only one PLPS cell line is reportedly available for analysis. A paucity of adequate cell line hinders the progress of research and treatments of PLPS. Thus, we aimed to establish and characterize a novel patient-derived cell line for PLPS. Using surgically resected tumor tissue from a 71-year-old male patient, we established the NCC-PLPS1-C1 cell line. The cells were maintained for more than 8 months and passaged ~ 40 times in the tissue culture condition. NCC-PLPS1-C1 cells were characterized by multiple genetic deletions and showed rapid growth, spheroid formation, and invasive potential. The NCC-PLPS1-C1 cells and the original tumor tissue shared similar kinase activity profiles for FES and PDGFR-β. NCC-PLPS1-C1 constantly proliferated, being suitable for the screening of anti-cancer drugs. A screen for the anti-proliferative effects of anti-cancer drugs on NCC-PLPS1-C1 cells showed a significant response for bortezomib, gemcitabine, romidepsin, topotecan, and vinblastine. In conclusion, NCC-PLPS1-C1 cells represent a useful tool for basic and pre-clinical studies related to PLPS, especially high-throughput drug screening.

多形性脂肪肉瘤（PLPS）是脂肪肉瘤的一种罕见亚型，其特征是存在多形性脂肪母细胞而没有明确的分子畸变；它占所有脂肪肉瘤的不到5%。PLPS 是一种侵袭性癌症，经常出现局部复发和转移，总体 5 年生存率约为 60%。由于在不能手术的情况下缺乏有效的治疗选择和对化疗药物的抵抗，需要新的疗法来治疗 PLPS。尽管源自患者的细胞系是基础和临床前研究的关键工具，但据报道只有一种 PLPS 细胞系可用于分析。缺乏足够的细胞系阻碍了 PLPS 研究和治疗的进展。因此，我们旨在建立和表征一种新型的患者来源的 PLPS 细胞系。使用从 71 岁男性患者手术切除的肿瘤组织，我们建立了 NCC-PLPS1-C1 细胞系。细胞在组织培养条件下保持8个月以上并传代~40次。NCC-PLPS1-C1 细胞的特点是多个基因缺失，并显示出快速生长、球体形成和侵袭潜力。NCC-PLPS1-C1 细胞和原始肿瘤组织具有相似的 FES 和 PDGFR-β 激酶活性谱。NCC-PLPS1-C1不断增殖，适合用于抗癌药物的筛选。对抗癌药物对 NCC-PLPS1-C1 细胞的抗增殖作用的筛选显示，硼替佐米、吉西他滨、罗米地辛、拓扑替康和长春碱有显着反应。综上所述，